Developing first-in-class therapeutic enhancers to revolutionize medical interventions
Developing first-in-class translational fidelity enhancers to revolutionize therapeutic interventions targeting mRNA translation processes. At Ribogenyx, we're dedicated to unlocking new frontiers in precision medicine through innovative technologies that enhance translational fidelity.
Completing his PhD and postdoc in mitochondrial genomics in the lab of Prof. Patrick Chinnery at the University of Cambridge, Angelos published the projects he led at Cell and Science Advances before joining Altos Labs. There, he applied his expertise in generating novel datasets aimed at discovering and validating novel drug targets.
With over a decade of combined academic and industry experience in age-related diseases, Maxime is driven by a deep passion for fundamental biology and the mechanisms of stress resilience mediated by mRNA translation. With a background in neurobiology and the genetics of aging, he is committed to improving the lives of individuals affected by age-related conditions.
Join us in October 2025 in pioneering translational fidelity technology